Siok-Hian Tay-Kelley, NP
Adult Health · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Siok-Hian Tay-Kelley’s office at (650) 498-6000 to ask if they take your plan before you enroll.
California Medical Board record
Licence C19493 · Cancelled
Licence status: Cancelled · since 1958 · University of Utah School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$13,048
Pharmacies billed $13,048 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
45 generic and fewer than 11 brand-name prescriptions · $13,048 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 56 | 12 | None | None | $13,048 |
| 2023 | 39 | 20 | 44% (17) | None | $532 |
| 2022 | 40 | 25 | 33% (13) | 0% | $978 |
| 2021 | 60 | 30 | 33% (20) | None | $25,657 |
| 2020 | 86 | 37 | 34% (29) | None | $29,420 |
| 2019 | 49 | 19 | 31% (15) | None | $1,228 |
| 2018 | 64 | 30 | 33% (21) | None | $1,118 |
| 2017 | 45 | 27 | None | None | $3,150 |
| 2016 | 98 | 39 | 19% (19) | 12% | $92,959 |
| 2015 | 37 | 25 | 54% (20) | None | $13,097 |
| 2013 | 12 | None | 0% (0) | None | $455 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 2 drugs
| Cyclobenzaprine | 12 | $547 | $46 |
| Oxycodone | 12 | $123 | $10 |
2021: 2 drugs
| Cyclobenzaprine | 15 | $392 | $26 |
| Oxycodone | 17 | $180 | $11 |
2020: 3 drugs
| Cyclobenzaprine | 22 | $345 | $16 |
| Oxycodone | 20 | $252 | $13 |
| Gabapentin | 13 | $169 | $13 |
2019: 1 drug
| Cyclobenzaprine | 14 | $154 | $11 |
2018: 2 drugs
| Oxycodone | 13 | $211 | $16 |
| Cyclobenzaprine | 11 | $98 | $9 |
2016: 1 drug
| Diphenoxylate-Atropine | 13 | $457 | $35 |
2013: 1 drug
| Warfarin | 11 | $229 | $21 |
Money from drug and device companies
$129 in 2025
| 2025 | 1 | 1 | None | $129 |
| 2024 | 4 | 5 | None | $595 |
| 2023 | 2 | 3 | None | $204 |
| 2022 | 2 | 2 | None | $241 |
| 2021 | 2 | 2 | None | $182 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tecvayli | $129 | 1 payment
|
See the published payment
| Janssen Biotech | Meals · 2025-04-12 | Tecvayli | $129 |
See earlier years (2024, 2023, 2022, 2021)
2024: $595
| Exelixis | Cabometyx | $205 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $141 | 1 payment
|
| Janssen Biotech | Tecvayli | $129 | 1 payment
|
| Astellas Pharma US | Padcev | $120 | 1 payment
|
2023: $204
| Exelixis | Cabometyx | $151 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $53 | 1 payment
|
2022: $241
| Astellas Pharma US | Padcev | $123 | 1 payment
|
| Jazz Pharmaceuticals | Rylaze | $118 | 1 payment
|
2021: $182
| E.R. Squibb & Sons L.L.C. | Opdivo | $122 | 1 payment
|
| SK Life Science | Xcopri | $60 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) · 2025 | Their institution | $242,479 |
| UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) · 2024 | Their institution | $222,593 |
| UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) · 2023 | Their institution | $115,564 |
| UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (M · 2022 | Their institution | $28,732 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568766442
- Licence
- CA 19493, CA 3322California C19493: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2200X (363LA2200X); Federal specialty code 364S00000X (364S00000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2011-01-06
- NPI last updated
- 2016-09-16
This is when the NPI record was last certified, not a medical board exam.